Sector
PharmaceuticalsOpen
₹2,850Prev. Close
₹2,838.95Turnover(Lac.)
₹1,887.86Day's High
₹2,861.55Day's Low
₹2,775.1552 Week's High
₹3,48552 Week's Low
₹1,850.25Book Value
₹310.96Face Value
₹2Mkt Cap (₹ Cr.)
35,068.45P/E
41.55EPS
68.36Divi. Yield
1.82Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 25.27 | 25.27 | 17.17 | 17.39 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,388.3 | 3,221.18 | 3,152.01 | 2,867.59 |
Net Worth | 3,413.57 | 3,246.45 | 3,169.18 | 2,884.98 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 3,140.64 | 2,718.59 | 2,196.42 | 1,825.35 |
yoy growth (%) | 15.52 | 23.77 | 20.32 | 1.16 |
Raw materials | -832.56 | -730.08 | -663.97 | -399.29 |
As % of sales | 26.5 | 26.85 | 30.22 | 21.87 |
Employee costs | -585.87 | -498.11 | -437.82 | -342.89 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 900.54 | 902.09 | 616.59 | 562.44 |
Depreciation | -120.96 | -111.49 | -91.29 | -57.14 |
Tax paid | -180.68 | -226.45 | -171.54 | -134.92 |
Working capital | 278.87 | 306.22 | 272.08 | 231.17 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.52 | 23.77 | 20.32 | 1.16 |
Op profit growth | -2.83 | 72.09 | -2.56 | -13.8 |
EBIT growth | 0.07 | 45.27 | 11.19 | -12.34 |
Net profit growth | 6.54 | 53.16 | 3.18 | -14.46 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 4,208.71 | 3,742.64 | 3,340.99 | 2,889.69 | 2,587.87 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 4,208.71 | 3,742.64 | 3,340.99 | 2,889.69 | 2,587.87 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 84.6 | 98.64 | 115.68 | 25.98 | 92.19 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,813.45 | 157.05 | 4,32,948 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,876.7 | 85.94 | 1,57,872.84 | 518 | 0.5 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,447.3 | 27.59 | 1,16,809.04 | 1,178.16 | 0.9 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,345.85 | 68.85 | 1,12,638.04 | 460 | 0.84 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,641.85 | 52.98 | 1,06,197.5 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Mannalal B Agrawal
Vice Chairman
Madhusudan B Agrawal
Managing Director
Yogesh Agrawal
Independent Director
Chandrakanth M Khetan
Vice President & CS
Gaurang Shah
Joint Managing Director
Rajesh M Agrawal
Independent Director
K H Viswanathan
Independent Director
Prabhakar Dalal
Independent Director
Anjana Grewal
Independent Director
David Rasquinha
Independent Director
Medha Joshi
Independent Director
Simi Thapar
Independent Director
Rajesh Shashikant Dalal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ajanta Pharma Ltd
Summary
Ajanta Pharma is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The companys business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.In branded generic business in emerging markets in Asia and Africa, Ajanta Pharmas products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The companys institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Maurit
Read More
The Ajanta Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2807.45 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ajanta Pharma Ltd is ₹35068.45 Cr. as of 13 Dec ‘24
The PE and PB ratios of Ajanta Pharma Ltd is 41.55 and 10.05 as of 13 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Ajanta Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ajanta Pharma Ltd is ₹1850.25 and ₹3485 as of 13 Dec ‘24
Ajanta Pharma Ltd's CAGR for 5 Years at 34.16%, 3 Years at 25.59%, 1 Year at 50.32%, 6 Month at 18.39%, 3 Month at -16.28% and 1 Month at 0.03%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice